BriaCell Therapeutics (BCT.TO), down near 1% in U.S. pre-market trade, has completed manufacturing clinical supplies of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy candidate for prostate cancer, the company said on Thursday.
BriaCell was awarded a US$2 million non-dilutive grant from the U.S. National Cancer Institute to support the manufacturing and planned clinical evaluation of Bria-PROS+ last August.
"The design of Bria-PROS+ is intended to support enhanced immune system activation while maintaining a favorable safety profile. We look forward to advancing Bria-PROS+ into the clinic as we seek to develop new treatment options for prostate cancer patients who do not respond to available therapies," said chief executive William Williams.
BriaCell's recent AACR preclinical poster presentation demonstrated Bria-PROS+ activating both adaptive and innate immunity, a statement added. The company believes these preclinical findings support further clinical evaluation as a potential immunotherapy for prostate cancer.
BriCell shares were last seen down US$0.04, to US$4.14, on in New York trading.